Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells
1Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, People's Republic of China.
Background:
Renal cell carcinoma (RCC) is a common urological system malignancy lack of effective therapeutic options. Upregulation of the Bcl-2 proteins was correlated with poor prognosis of RCC, suggesting that BH-3 mimetics may be a promising treatment option. ABT-263 is a BH3 mimetic that possesses anti-tumor effects. TW-37 is another inhibitor of Bcl-2 family protein with potential anti-tumor activities. However, since their effect as single agent is limited, combination treatment represents a strategy to improve the efficiency. We studied the ABT-263 in combination with TW-37 and analyzed the molecular mechanisms of action in RCC cells.
Methods:
MTT and colony formation assays were used to measure the proliferation of RCC cells. Transwell assay was used to assay the migration and invasion of RCC cells. Cell cycle distribution and apoptosis were measured using the flow cytometry and apoptotic nucleosome assay, respectively. Western blotting was performed to measure the change of proteins. The anti-tumor effects of ABT-263, TW-37 and their combination were also evaluated in vivo.
Results:
Cotreatment of TW-37 and ABT-263 synergistically repressed the proliferation of RCC cells. TW-37 and ABT-263 also synergistically inhibited the migration and invasion of RCC cells It was also showed that TW-37 and ABT-263 synergistically induced cell cycle arrest at the G2/M phase. Furthermore, increased apoptosis was observed after exposure to TW-37 and ABT-263. Mechanism investigation showed that TW-37 and ABT-263 synergistically induced apoptosis via the mitochondrial pathway and relied on the activation of Bax and caspases. Furthermore, ERK signaling pathway activation was detected after treated with TW-37 and ABT-263. Finally, TW-37 and ABT-263 also synergistically repressed the growth of RCC cells in xenograft mice.
Conclusion:
In summary, our data demonstrated that combined treatment with TW-37 and ABT-263 exhibited synergistic RCC cell death and this combination may be applied as an effective therapeutic strategy against RCC.
Insights
Combining BH3 mimetics TW-37 and ABT-263 synergistically kills renal cell carcinoma (RCC) cells. This combination therapy shows promise for treating RCC by inhibiting proliferation, migration, and inducing apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Renal cell carcinoma (RCC) is a prevalent urological malignancy with limited effective treatments.
- Upregulation of Bcl-2 proteins correlates with poor RCC prognosis, indicating BH-3 mimetics as potential therapeutic agents.
- ABT-263 and TW-37 are BH-3 mimetics with demonstrated anti-tumor effects, but their efficacy as single agents is limited.
Purpose of the Study:
- To investigate the synergistic anti-tumor effects of combining ABT-263 and TW-37 in renal cell carcinoma (RCC) cells.
- To elucidate the molecular mechanisms underlying the combined action of ABT-263 and TW-37 in RCC.
Main Methods:
- Cell proliferation was assessed using MTT and colony formation assays.
- Cell migration and invasion were evaluated via Transwell assays.
- Cell cycle distribution and apoptosis were measured by flow cytometry and nucleosome assays, respectively. Protein expression and signaling pathway activation (ERK) were analyzed by Western blotting. In vivo efficacy was tested in xenograft mouse models.
Main Results:
- Combined TW-37 and ABT-263 treatment synergistically inhibited RCC cell proliferation, migration, and invasion.
- The combination induced G2/M phase cell cycle arrest and significantly increased apoptosis through the mitochondrial pathway, involving Bax and caspase activation.
- ERK signaling pathway activation was observed, and the combination therapy synergistically repressed tumor growth in vivo.
Conclusions:
- Combined treatment with TW-37 and ABT-263 demonstrates synergistic anti-cancer effects in RCC.
- This combination therapy represents a promising strategy for the effective treatment of renal cell carcinoma.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy